Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
Open Access
- 17 August 2022
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-8
Abstract
Background: Tumor necrosis factor receptor-associated factor 6 (TRAF6) can regulate the activation of inflammatory signaling pathways by acting as an E3 ubiquitin ligase, which enhances B cell activation. This study aimed to evaluate the expression of TRAF6 in the peripheral blood B cells of myasthenia gravis (MG) patients and analyze the relationships between TRAF6 expression and clinical characteristics. Method: In our study, the expression level of TRAF6 in peripheral blood B cells of 89 patients was measured by flow cytometry compared with that of healthy subjects. The effects of disease severity, MG classification and immunotherapy on TRAF6 expression level were also analyzed. Results: In our study, TRAF6 expression was elevated in CD19+ B cells and CD19+CD27+ memory B cells in generalized MG (GMG) patients compared with ocular MG (OMG) patients (p = 0.03 and p = 0.03, respectively). There was a significant positive correlation between the TRAF6 expression level and disease severity in both OMG patients and GMG patients (CD19+ B cells: OMG: p < 0.001, r = 0.89; GMG: p = 0.001, r = 0.59; CD29+CD27+ B cells: OMG: p = 0.001, r = 0.80; GMG: p = 0.048, r = 0.38). TRAF6 expression was significantly elevated in CD19+ B cells and CD19+CD27+ memory B cells in GMG with acute aggravation compared with GMG in MMS (p = 0.009 and p = 0.028, respectively). In the eleven MG patients who were followed, TRAF6 expression in B cells and memory B cells was significantly decreased after treatment (p = 0.03 and p < 0.01, respectively). Conclusion: TRAF6 is potentially a useful biomarker of inflammation in patients with MG, and might be used to evaluate the effectiveness of treatment.Keywords
Funding Information
- Youth Incubation Fund of Tianjin Medical University General Hospital (ZYYFY2019008)
- National Natural Science Foundation of China (82071907, 82171338)
This publication has 30 references indexed in Scilit:
- Tumor necrosis factor receptor‐ associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune systemImmunological Reviews, 2015
- Memory B cellsNature Reviews Immunology, 2015
- Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia GravisBioMed Research International, 2015
- IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravisActa Neuropathologica Communications, 2015
- Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosusLupus, 2014
- Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: Roles of IL-17 and TNF-αJournal of Autoimmunity, 2014
- Diagnostic and clinical classification of autoimmune myasthenia gravisJournal of Autoimmunity, 2014
- Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patientsJournal of Neuroimmunology, 2013
- MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1Journal of Clinical Immunology, 2012
- Neuroprotective effect of early and short-time applying sophoridine in pMCAO rat brain: Down-regulated TRAF6 and up-regulated p-ERK1/2 expression, ameliorated brain infaction and edemaBrain Research Bulletin, 2012